Literature DB >> 18508996

Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

Thorvardur R Halfdanarson1, Joseph Rubin, Michael B Farnell, Clive S Grant, Gloria M Petersen.   

Abstract

Pancreatic endocrine tumors (PETs) are uncommon tumors with an annual incidence <1 per 100 000 person-years in the general population. The PETs that produce hormones resulting in symptoms are designated as functional. The majority of PETs are non-functional. Of the functional tumors, insulinomas are the most common, followed by gastrinomas. The clinical course of patients with PETs is variable and depends on the extent of the disease and the treatment rendered. Patients with completely resected tumors generally have a good prognosis, and aggressive surgical therapy in patients with advanced disease may also prolong survival. The epidemiology, prognosis, and established and novel prognostic markers of PETs are reviewed.

Entities:  

Mesh:

Year:  2008        PMID: 18508996      PMCID: PMC2693313          DOI: 10.1677/ERC-07-0221

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  166 in total

1.  Management of islet cell carcinoma.

Authors:  A Legaspi; M F Brennan
Journal:  Surgery       Date:  1988-12       Impact factor: 3.982

Review 2.  Malignant endocrine tumor of the pancreas associated with von Recklinghausen's disease.

Authors:  Takashi Fujisawa; Tatsuya Osuga; Mitsuo Maeda; Norikazu Sakamoto; Tetsuo Maeda; Kazuhiko Sakaguchi; Yutaka Onishi; Masanori Toyoda; Hiroaki Maeda; Katsufumi Miyamoto; Nobuaki Kawaraya; Chosei Kusumoto; Takashi Nishigami
Journal:  J Gastroenterol       Date:  2002-01       Impact factor: 7.527

3.  Pancreatic islet cell tumors.

Authors:  T A Broughan; J D Leslie; J M Soto; R E Hermann
Journal:  Surgery       Date:  1986-06       Impact factor: 3.982

4.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

5.  Prognostic and immunohistochemical validation of the capella classification of pancreatic neuroendocrine tumours: an analysis of 82 sporadic cases.

Authors:  M F Heymann; M Joubert; J Nemeth; B Franc; J Visset; A Hamy; J le Borgne; J C le Neel; A Murat; S Cordel; M F le Bodic
Journal:  Histopathology       Date:  2000-05       Impact factor: 5.087

6.  Islet cell carcinoma of the pancreas. A study of 98 patients.

Authors:  S Venkatesh; N G Ordonez; J Ajani; P N Schultz; R C Hickey; D A Johnston; N A Samaan
Journal:  Cancer       Date:  1990-01-15       Impact factor: 6.860

7.  Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance.

Authors:  Yuan-Jia Chen; Alexander Vortmeyer; Zhengping Zhuang; Steve Huang; Robert T Jensen
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

8.  Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study.

Authors:  Lucio Gullo; Marina Migliori; Massimo Falconi; Paolo Pederzoli; Rossella Bettini; Riccardo Casadei; Gianfranco Delle Fave; Vito D Corleto; Claudio Ceccarelli; Donatella Santini; Paola Tomassetti
Journal:  Am J Gastroenterol       Date:  2003-11       Impact factor: 10.864

9.  Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs).

Authors:  A Goto; T Niki; Y Terado; J Fukushima; M Fukayama
Journal:  Histopathology       Date:  2004-10       Impact factor: 5.087

Review 10.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

View more
  103 in total

Review 1.  Clinical pathways for pancreatic neuroendocrine tumors.

Authors:  Angela Alistar; Max Sung; Michelle Kim; Randall F Holcombe
Journal:  J Gastrointest Cancer       Date:  2012-12

Review 2.  Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.

Authors:  Roeland F de Wilde; Barish H Edil; Ralph H Hruban; Anirban Maitra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

3.  Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: results of a single-center series.

Authors:  Riccardo Casadei; Claudio Ricci; Raffaele Pezzilli; Davide Campana; Paola Tomassetti; Lucia Calculli; Donatella Santini; Nicola Antonacci; Francesco Minni
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

4.  Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation.

Authors:  Martin B Niederle; Bruno Niederle
Journal:  Oncologist       Date:  2011-04-05

5.  Expression of CD24, a Stem Cell Marker, in Pancreatic and Small Intestinal Neuroendocrine Tumors.

Authors:  Safia Salaria; Anna Means; Frank Revetta; Kamran Idrees; Eric Liu; Chanjuan Shi
Journal:  Am J Clin Pathol       Date:  2015-10       Impact factor: 2.493

6.  Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.

Authors:  Joo Young Kim; Jacqueline A Brosnan-Cashman; Soyeon An; Sung Joo Kim; Ki-Byung Song; Min-Sun Kim; Mi-Ju Kim; Dae Wook Hwang; Alan K Meeker; Eunsil Yu; Song Cheol Kim; Ralph H Hruban; Christopher M Heaphy; Seung-Mo Hong
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

Review 7.  Update on pancreatic neuroendocrine tumors.

Authors:  Logan R McKenna; Barish H Edil
Journal:  Gland Surg       Date:  2014-11

Review 8.  The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.

Authors:  Mauro Cives; Jonathan Strosberg
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

9.  High pre-operative fasting blood glucose levels predict a poor prognosis in patients with pancreatic neuroendocrine tumour.

Authors:  Yitao Gong; Zhiyao Fan; Pin Zhang; Yunzhen Qian; Qiuyi Huang; Shengming Deng; Guopei Luo; He Cheng; Kaizhou Jin; Quanxing Ni; Xianjun Yu; Chen Liu
Journal:  Endocrine       Date:  2020-08-29       Impact factor: 3.633

10.  Impact of splenectomy on thrombocytopenia, chemotherapy, and survival in patients with unresectable pancreatic cancer.

Authors:  Timothy R Donahue; Kevork K Kazanjian; William H Isacoff; Howard A Reber; O Joe Hines
Journal:  J Gastrointest Surg       Date:  2010-03-23       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.